Healthcare provider profile · identity verified

David B Cowan, MD

Family Practice · BAINBRIDGE ISLAND, WA · NPI 1487763405

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	424	116
Losartan Potassium	Losartan Potassium	290	87
Amlodipine Besylate	Amlodipine Besylate	280	79
Tamsulosin Hcl	Tamsulosin Hcl	197	53
Levothyroxine Sodium	Levothyroxine Sodium	162	40
Simvastatin	Simvastatin	135	38
Metformin Hcl	Metformin Hcl	132	34
Olmesartan Medoxomil	Olmesartan Medoxomil	131	39
Allopurinol	Allopurinol	122	29
Gabapentin	Gabapentin	83	25
Metoprolol Succinate	Metoprolol Succinate	77	23
Lisinopril	Lisinopril	74	20
Rosuvastatin Calcium	Rosuvastatin Calcium	69	30
Hydrochlorothiazide	Hydrochlorothiazide	66	18
Mirtazapine	Mirtazapine	65	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	64	18
Escitalopram Oxalate	Escitalopram Oxalate	48	13
Omeprazole	Omeprazole	48	14
Jardiance	Empagliflozin	47	11
Lovastatin	Lovastatin	47	14
Pravastatin Sodium	Pravastatin Sodium	46	13
Fluoxetine Hcl	Fluoxetine Hcl	40	12
Estradiol	Estradiol	39	suppressed
Valsartan	Valsartan	38	12
Finasteride	Finasteride	35	suppressed
Oxycodone Hcl	Oxycodone Hcl	35	suppressed
Sertraline Hcl	Sertraline Hcl	35	suppressed
Telmisartan	Telmisartan	35	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	33	suppressed
Trulicity	Dulaglutide	33	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Terazosin Hcl	Terazosin Hcl	31	suppressed
Alprazolam	Alprazolam	29	suppressed
Alendronate Sodium	Alendronate Sodium	28	suppressed
Buspirone Hcl	Buspirone Hcl	28	suppressed
Citalopram Hbr	Citalopram Hydrobromide	28	suppressed
Eliquis	Apixaban	27	11
Atenolol	Atenolol	25	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	24	suppressed
Carvedilol	Carvedilol	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	23	suppressed
Bupropion Xl	Bupropion Hcl	22	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	22	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	21	suppressed
Ozempic	Semaglutide	21	suppressed
Fluticasone Propionate	Fluticasone Propionate	20	11
Risedronate Sodium	Risedronate Sodium	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	suppressed
Testosterone	Testosterone	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Famotidine	Famotidine	16	suppressed
Liothyronine Sodium	Liothyronine Sodium	15	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	15	suppressed
Trazodone Hcl	Trazodone Hcl	15	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	14	suppressed
Clopidogrel	Clopidogrel Bisulfate	14	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	14	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Felodipine Er	Felodipine	13	suppressed
Furosemide	Furosemide	13	suppressed
Colesevelam Hcl	Colesevelam Hcl	12	suppressed
Glipizide	Glipizide	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Potassium Chloride	Potassium Chloride	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Fentanyl	Fentanyl	11	suppressed
Ibandronate Sodium	Ibandronate Sodium	11	suppressed
Indapamide	Indapamide	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error